ovarian cancer research alliance(new york city)

Ovarian Cancer Research Alliance

Ovarian cancer research alliance provides education about ovarian cancer, supportive services to persons affected by ovarian cancer and fosters alliances to further those purposes., contact number.

212-268-1002

Mailing Address

14 Pennsylvania Plaza, Suite 2110 New York, NY 10122

Contact Page

https://ocrahope.org/about/contact/

Ovarian Cancer Research Alliance

From their website:

Ovarian Cancer Research Alliance (OCRA) is the leading organization in the world fighting ovarian cancer from all fronts, including in the lab and on Capitol Hill, while supporting women and their families.

three cornerstones of our mission

Funding research.

OCRA’s ongoing investment in the most promising scientific research is funding discoveries, creating new treatments, and hastening desperately needed breakthroughs.

ADVOCATING FOR PATIENTS

We are  THE  voice for the ovarian cancer community, working with legislators to ensure federal ovarian cancer research and education funding, patient safety, and access to high-quality care are protected on Capitol Hill.

SUPPORTING SURVIVORS

Our programs help women navigate an overwhelming diagnosis, supporting patients and their families when and where they need it most.

• Research and Clinical Trials

Home » About Ovarian Cancer » Research and Clinical Trials

Ovarian Cancer Research

In collaboration with Stand Up To Cancer and our partner, Ovarian Cancer Research Alliance, NOCC supported the Ovarian Cancer Dream Team – the first of its kind in the history of ovarian cancer research. This outstanding team began its work in July 2015, leveraging collaborative team science.

The SU2C-Ovarian Cancer Research Alliance-National Ovarian Cancer Coalition Dream Team focused on developing new therapies that target DNA repair and expanding PARP inhibitor use to women even beyond those with BRCA mutations. The team aimed to identify women at increased risk for ovarian cancer by screening for inherited mutations in genes linked to DNA repair, enabling these high-risk women to choose lifesaving preventative measures. Learn more about the SU2C-Ovarian Cancer Research Alliance-National Ovarian Cancer Coalition Dream Team.

In 2012, NOCC partnered with the GOG (Gynecologic Oncology Group) in funding the LIvES Study, overseen by the University of Arizona Cancer Center. The LIvES research initiative focused on a randomized, controlled trial study to test hypotheses relating dietary intake and physical activity to improved progression-free survival and quality of life among women diagnosed with ovarian cancer.

In 2011, NOCC partnered with Ovarian Cancer Research Fund (OCRF) and funded “The Ann Schreiber Ovarian Cancer Research Training Program of Excellence: A Study by Dr. Ruth Perets”.

Working to Improve Outcomes

Clinical trials lead to new and improved standards of care for ovarian cancer. For anyone who chooses to join a clinical trial, they will receive the best care available and help themselves as well as others by contributing to research.

What is an ovarian cancer clinical trial? Why should I consider participating?

Clinical trials are research studies designed to find ways to improve health, answer scientific questions and find better ways to prevent, diagnose or treat cancer. For many women with ovarian cancer, investigational treatments may offer new hope. Through participation in these trials, patients may receive access to new therapy options that are not available beyond the clinical trial setting.

Clinical trial phases

There are four main phases of clinical trials. This allows researchers to ask and answer questions as the trial progresses to ensure their information is reliable and protects the patient.

Phase I: Researchers first test a new drug or treatment in a small group (20-80) to evaluate its safety, determine safe dosages and identify side effects.

Phase II: The study drug or treatment is given to a larger group (100-300) to see if it’s effective and to further evaluate its safety; often, new combinations of drugs are tested.

Phase III: Large groups (1,000-3,000) are given the study drug or treatment to confirm its efficacy, monitor side effects, compare it to commonly used treatments and collect information that will allow the drug or treatment to be used safely. Usually, patients are put into at least two groups – a standard group and an unspecified group, known as randomization . 

Phase IV: This focuses on long-term effectiveness and side effects of drug or treatment post-FDA approval, and is conducted over an extended period of time.

Myths and misconceptions about clinical trials

Questions to ask about clinical trials:.

It’s advisable to bring a family member or friend  along to learn about a clinical trial. Ask them to take notes and step in with questions if needed, such as:

• Is a clinical trial a treatment option for me?
• Why is the study being done?
• Who’s running it?
• Am I eligible to participate?
• What phase is the clinical trial in?
• What are the benefits and risks?
• Will my insurance cover the costs?
• How long will the study last?
• Will you still be my oncologist?
• What is informed consent?
• What are my rights as a patient?  Can I leave the trial at any time?

Will I get a placebo?

No. Clinical trials test the safety and benefits of new treatments as well as new combinations (or new doses) of standard treatments. You will get either the new treatment and/or the standard treatment. Sometimes, patients get the standard treatment plus a placebo rather than the standard treatment plus the new treatment (being studied).

Will my insurance cover the cost?

A growing number of states have passed legislation or instituted special agreements requiring health plans to pay the cost of routine medical care received by a participant in a clinical trial. Learn more about paying for clinical trials.

Types of trials

Treatment trials.

These test the effectiveness of new treatments or ways of using existing treatments in people with cancer. Combinations of different treatment types may also be tested. Treatment trials can include new drugs or new combinations of current drugs, new surgery or radiation therapy techniques. They are also used to test vaccines or other therapies that stimulate the immune system to fight cancer. 

Screening trials

These trials are conducted to find new ways to detect cancer, especially in the early stages.

Quality-of-life trials

These examine ways to increase the level of health and comfort for cancer patients.

How do I find a clinical trial?

If you are thinking about joining a clinical trial as a treatment option, the best place to start is to talk with your doctor or another member of your health care team. Often your doctor may know about a clinical trial that could be a good option for you. He or she may also be able to search for a trial for you, provide information, and answer questions to help you decide about joining a clinical trial.

You can typically find the most recently updated listing of clinical trials online:

• Clinicaltrials.gov is a resource provided by the U.S. National Library of Medicine; it is a database of privately and publicly funded clinical studies conducted around the world
• Centerwatch.com is a clinical trials listing service for ovarian cancer medical research trials actively recruiting patients
• Emergingmed.com Clinical Trial Navigation Service can assist in looking for clinical trials by filling a short questionnaire

Make a donation

Find a support group.

12221 Merit Drive Suite 1950 Dallas, TX 75251

[email protected]

Information: 888-OVARIAN (888-682-7426) Direct: 214-273-4200

Stay Connected. Join our newsletter to stay up to date on our events and news.

For Patients

• Newly Diagnosed

Support & Resources

• Stories of Inspiration
• For Caregivers

About Ovarian Cancer

What is Ovarian Cancer

• Risk Factors

Ovarian Cancer Signs and Symptoms

Types and Stages

• Treatment Options
• Chemotherapy

Programs and Resources

Peer Support Programs

Online Education Programs

Support Services

• Ovarian Cancer News
• Mission and Vision

Privacy Policy

How to Help

• Ways To Give
• NOCC Communities
• Fundraise for Ovarian Cancer Support
• NOCC Events
• Share Your Story
• Honor a Loved One

© 2024 ovarian.org.

• Support & Resources
• Survivor Peer Support Group
• Caregiver Peer Support Group
• Online Support forum
• Animated Patient Guide – You and Ovarian Cancer
• Facebook Live Educational Series
• Quality of Life Education and Support
• Ovarian Cancer Care Package
• Meal Delivery
• One-on-One Professional Counseling
• Financial Assistance
• What is Ovarian Cancer?
• Signs and Symptoms
• Types & Stages

Ovarian Cancer Statistics

In the United States, doctors must report any diagnosis of cancer to a state registry. The federal government, through the Centers for Disease Control and Prevention’s National Program of Cancer Registries, oversees the registries in 45 states, the District of Columbia and three territories. The Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute funds the remaining five statewide cancer registries. Together, the two programs cover the country’s population.

The following ovarian cancer statistics come primarily from the most recent findings of the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute. SEER numbers are age-adjusted and based on actual data.

SEER data is available for most data through 2018. More recent statistics are projections from the American Cancer Society.  

Keep up with the latest statistics by  joining our email list .

Ovarian Cancer Statistics at a Glance

• The American Cancer Society estimates that in 2022, about 19,880 new cases of ovarian cancer will be diagnosed and 12,810 women will die of ovarian cancer in the United States.
• Mortality rates for ovarian cancer have declined only slightly in the forty years since the “War on Cancer” was declared. However, other cancers have shown a much greater reduction in mortality, due to many factors.  
• The Surveillance, Epidemiology and End Results (SEER) Program reports that in 2019 in the United States approximately 233,565 women were alive who had been diagnosed with ovarian cancer (including those who had been cured of the disease).
• Ovarian cancer accounts for 2.5 percent of cancers in women.
• While the 11th most common cancer among women, ovarian cancer is the fifth leading cause of cancer-related death among women.
• Ovarian cancer is the deadliest of gynecologic cancers.
• Mortality rates are slightly higher for African American women than for Caucasian women.

Ovarian Cancer Lifetime Risk and Survival Statistics

It’s important to be aware of the risk factors for developing ovarian cancer, as well as average rates of diagnosis. Five-year survival rates are commonly used to compare different cancers. Survival rates vary greatly depending on the stage of diagnosis.

• A woman’s lifetime risk of developing ovarian cancer is 1 in 78.
• A woman’s lifetime risk of dying from invasive ovarian cancer is 1 in 108.
• Ovarian cancer survival rates are much lower than other cancers that affect women.
•  The relative five-year survival rate for ovarian cancer is 49.7% percent.
• Women diagnosed at an early stage—before the cancer has spread—have a much higher five-year survival rate than those diagnosed at a later stage.
• Approximately 17 percent of ovarian cancer patients are diagnosed early with early stage disease.

Ovarian Cancer Statistics By Age

• Ovarian cancer rates are highest in women aged 55-64 years.
• The median age at which women are diagnosed with ovarian cancer is 63, meaning that half of women are younger than 63 when diagnosed with ovarian cancer and half are older.
• The median age of death from ovarian cancer is 70.

Ovarian Cancer Cases By Race

For more information, visit:

• The National Cancer Institute’s Surveillance, Epidemiology and End Results Program
• SEER Stat Fact Sheets: Ovary Cancer
• The Center for Disease Control and Prevention’s National Program of Cancer Registries Website
• American Cancer Society’s Ovarian Cancer Key Statistics

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest news
• Stock market
• Premium news
• Biden economy
• EV Deep Dive
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds
• Top Mutual Funds
• Highest Open Interest
• Highest Implied Volatility
• Stock Comparison
• Advanced Charts
• Currency Converter
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Mutual Funds
• Credit cards
• Balance transfer cards
• Cash-back cards
• Rewards cards
• Travel cards
• Personal loans
• Student loans
• Car insurance
• Morning Brief
• Market Domination
• Market Domination Overtime
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Ovarian cancer research alliance celebrates landmark year of achievements in 2023, surpassing fundraising goals and accelerating research in gynecologic cancers.

NEW YORK , Jan. 17, 2024 /PRNewswire/ -- Ovarian Cancer Research Alliance (OCRA) proudly announces the successful culmination of an extraordinary year, marking 2023 as a milestone in our pursuit of advancing knowledge, treatment, and support for individuals impacted by ovarian and related gynecologic cancers.

Underscoring a testament to the collective commitment to defeating these diseases, OCRA exceeded its year-end fundraising target of $2 million , thanks to the unwavering support of our dedicated community and partners.

"Historically, 2023 has been a year of unparalleled achievement for OCRA," said Audra Moran , President and CEO. "Our achievements this year have bolstered our commitment and energized our efforts to drive significant progress in understanding, preventing, and treating ovarian and related gynecologic cancers."

Key highlights from OCRA's successful year include:

Historic Research Investment

One of the most significant milestones was OCRA's funding of $9.2 million in research grants, the most in our organization's history.

Genetic Testing & Prevention

OCRA's influential message on the critical importance of risk awareness and prevention resonated with millions, with more than 3,000 people taking advantage of the free genetic test kits we offered. Notably, about 100 individuals identified genetic mutations, empowering them to take proactive preventive measures.

Expanded Mission

Recognizing the interconnectedness of ovarian and related gynecologic cancers, OCRA expanded its mission accelerating progress, acknowledging commonalities between these diseases, and broadening our impact on patients' lives.

Patient Support Impact

The expansion of OCRA's patient support programs saw a record number of individuals and families helped with navigating the complexities of diagnosis, treatment, and life beyond cancer. In 2023, OCRA fielded more than 2,100 calls on the Patient Support Line, impacted more than 200 people through our Woman to Woman peer mentor program, and had more than 10,000 participate in our myriad of programs, including Staying Connected Support Series, community building Art & Book Club sessions, clinical trial navigator, online community, and more.

Advocacy Drives Change

OCRA's advocacy efforts made substantial strides in 2023, meeting with over 380 Congressional offices, contributing to securing expanded Medicare coverage for genetic testing, garnering support for federal education programs, addressing chemotherapy drug shortages, and initiating research into health disparities.

The achievements of 2023 set the stage for an even more promising future. OCRA is poised to launch a groundbreaking patient registry, a national Data Commons, a doctor finder tool, a health equity grant, and more.

Ovarian Cancer Research Alliance (OCRA) is the largest global organization dedicated to advancing ovarian cancer research while supporting patients and their families. As the voice for ovarian cancer and related gynecologic cancers, OCRA funds private research, advocates for increased federal research and awareness funding, educates the public, and provides patient support to ensure early diagnosis, improved treatment, and quality of life for survivors.

View original content: https://www.prnewswire.com/news-releases/ovarian-cancer-research-alliance-celebrates-landmark-year-of-achievements-in-2023-surpassing-fundraising-goals-and-accelerating-research-in-gynecologic-cancers-302036512.html

SOURCE Ovarian Cancer Research Alliance

Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. To further refine your search, toggle appropriate sections on or off.

Home > Locations > New York City

New York City

Address Fort Wadsworth Staten Island NY 10305 United States

Upcoming Events

• No events in this location
• About This Blog
• Blog Policies
• Tips for Contributors

Digging Into Data Shows Cancer’s Effects on Ethnic Groups

Liquid Biopsy: Promises and Problems

An Important Skin Cancer Prevention Reminder: Don’t Fry

Colorectal Cancer: Preventive Measures, a New Treatment Approach, and Mortality Disparities

AACR Annual Meeting 2019: Past, Present, and Future of CDK4/6-targeted Therapeutics

Annual Meeting 2022: AACR Project GENIE Delivers More Treasure

Studying Blood Vessels to Improve Breast Cancer Outcomes

FDA Approvals Bring New Hope for Patients With BRCA-mutant Ovarian Cancer

Disparities Conference Unites Researchers, Patients, and Policymakers 

Women in Science: AACR Leaders Share Their Stories

Cancel reply

Your email address will not be published. Required fields are marked *

Join the Discussion (max: 750 characters)...

This site uses Akismet to reduce spam. Learn how your comment data is processed .

• AACR Runners for Research
• AACR-Bristol Myers Squibb Fellowships
• 2024 TCS New York City Marathon

July 13, 2020 PORTABLE DIAGNOSTIC IMAGING DRIVES THE "SEEING IS BELIEVING" GEN-Z MOVEMENT A survey of recent med-school graduates (of 2020), recently certified Emergency Responders and front-line recruits from New York nursing programs stamps a distinctly future-bound vision for diagnostic methodologies and treatment protocols. "This is a generation that did not experience life without the internet or the smart phone", and whose views of patient care is most often fast-tracked by current innovations and sustainable alternatives that boldly paved the road to our "new normal". This same generation that defines the future of medicine makes the advancement of PORTABLE ULTRASOUND TECHNOLOGY a timely upgrade in our medical diagnostic community. (SEE ARTICLE LINK)

Dec. 22, 2019 TODAY'S RADIOTHERAPY: CYBERKNIFE TECHNOLOGY (part 1) MEETING TODAY’S CHALLENGES FOR CANCER THERAPY Since the advent of radiation therapy (and the invention of the x-ray) over a century ago, the noninvasive treatment approach of radiotherapy continues to be recognized as one of the most forward-thinking technologies in the pursuit of targeting cancer tumors. The CyberKnife® Robotic RadioSurgery System represents the latest performance innovation in this modality for treating benign and malignant tumors as well as other chronic disorders. (SEE ARTICLE LINK)

Nov. 13, 2019 Community Leadership Power Meeting for First Responders Health Concerns- PILOT POWER-LUNCHEON MEETING #1 marked the first coordinated assembly of community-minded New Yorkers brought together to discuss the major concerns relating to public health and wellness among first responders. This conference pilot was produced by the NY Cancer Resource Alliance or NYCRA (a health education-based LINKEDIN group) and sponsored by AngioFoundation director Dr. Robert L. Bard. Other main guests included Director of Medical Operations /NY State Trooper Surgeons PBA MICHAEL BROOKS (Albany, NY) and Mrs. Mary Paterson, supporter of NY rescuers and wife of the 55th NYS Governor David Paterson. Both were invited because of their state government perspectives which opened wider insight and resource information about healthcare challenges of state and city government safety workers. The next speaker was celebrity wellness author and producer CAROL ALT who graced the discussion with her vast experience in Prevention and Early Detection alongside her life-long support for the FDNY. Meanwhile, on the healthcare side was leading cancer diagnostic specialist DR. ROBERT BARD, NYCRA mental health advisor JESSICA GLYNN, LCSW and physician DR. GEORGE LIAKEAS (provider of IvyGene cancer blood testing in NYC)- chosen for their clinical perspectives on clinical matters. Together, they formed the first Round Table Leadership Collaboration group. (SEE ARTICLE LINK)

Oct. 12, 2019 BEYONCÉ'S DAD BRINGS "NEW AMMO" TO MALE BREAST CANCER BATTLE Survivor Michael Singer (L) gives appreciation to Mathew Knowles (R) at Dr. Oz show for going public with his breast cancer for global awareness. Recent data reflecting actual cases about male breast cancer has finally reached the tipping point in the visibility scale as more news coverage from advocacy groups and victims finally ‘going public’ have filled the media. Thanks to survivors like Mathew Knowles (music producer and father of Beyoncé) who elected to publicize his breast cancer significantly contributed to public awareness, identifying this issue as a serious threat to public health. “One of our main objectives at the Male Breast Cancer Coalition is to publish all survivor stories to alert the men at large that this is not a cancer to ignore… it’s not so RARE or IMPOSSIBLE to contact,” states Cheri Ambrose, president. “Learning about Mr. Knowles’ story from the newspapers and Good Morning America, and then sharing airtime with him at Dr. Oz was such a powerful sign of support to our advocacy mission because he elected to use his own story and his celebrity to get people to pay attention. This is the kind of generosity that can truly save a lot of lives just on pure awareness alone!” ( SEE ARTICLE LINK)

The NEW YORK CANCER RESOURCE ALLIANCE (or NYCRA) is a self-funded ( Linkedin Based ) independent volunteer group of non-profit foundations/charities, researchers, educators, community leaders and survivors collaborating to bring new support for cancer patients and survivors. We form a unique network of caregivers joined to establish a support system for one another- while driven to help those who need additional resources, technical updates or empowerment on the road to recovery.

NO POLITICS: We cut through the corporate red tape that tends to limit (and inhibit) most non-profit groups. We do this by simply reaching out, building relationships, extending a hand to help and joining LIKE-MINDS to make things happen.

Our ACTION PLAN includes: - AWARENESS EFFORTS through public education - PARTNERSHIPS on joint projects with cancer resources - OUTREACH WORK to all cancer orgs, resources & survivors - PUBLISHING cancer care news, articles, videos & book projects - BUILDING new educational projects & resource groups

If you are a clinical professional, a survivor, a community leader or a caregiver, we want to meet you!

* This is a private group by invitation only. Our moderators reserve the right to flag any uninvited parties in order to keep our group members' privacy and the core theme of our community.

"BE MY HERO- GET CHECKED NOW!" In my tenure as one of the founding directors of the Male Breast Cancer Coalition, I have met so many brave and inspiring men who have come forward about this plaguing disease. Against the odds, they stepped up to get a complete diagosis, underwent the process of cancer treatment and are still with us today- walking this earth to spread the word to others about how REAL Male Breast Cancer truly is! Recently, I have met a growing number of FIREFIGHTERS in our area who fell prey to this disorder. As OCCUPATIONAL HAZARDS go, first responders carry some of the highest risk for cancers due to the exposure to some of the most horrible toxins. But the real danger is the stigma about getting Breast Cancer that keeps them from getting checkups. Thanks to NYCRA's "Get Checked Now" campaign, more and more are getting our message on time to address the cancer, and to stay vigilant about EARLY DETECTION & PREVENTION about this cancer and all other cancers that threaten our lives.

--Cheri Ambrose, www. mbcscan.com & www.malebreastcancercoalition.org

CANCER SPEAKER SERIES ON EARLY DETECTION & PREVENTION: FIGHTING CANCER THROUGH PUBLIC EDUCATION NYCRA is a volutneer union of caregivers, educators, clinical professionals and survivors-turned-crusaders. One of our most powerful tools to help victims fight (and beat) cancer is AWARENESS. The medical partners and public advocates of NYCRA in conjunction with Awareness for a Cure and a list of cancer foundations offers some of the most enlightening and compassionate volunteer speakers to conduct presentations about public health awareness to bring comprehensive cancer education to large community groups & private orgs. We have some of the most recognized and dynamic coaches and speakers dedicated to bringing better understanding about cancer to all New Yorkers. Our seminars cover a wide variety of useful topics, current statistics, resources and the latest innovations. For more info. on our traveling speaker series or to inquire about booking an event, contact us at: [email protected]

(Top video: courtesy of Awarenessforacure.org and Male Breast Cancer Coalition. Bottom Video: Courtesy of Dr. Noelle Cutter)

"LIVING ROOM SEMINARS": THE NEW TREND IN PUBLIC EDUCATION April 19, 2019, Dix Hills, NY- Stem Cell Specialist Dr. Andrew J. Rochman test-drove a new and growing trend in private seminars and clinical public speaking. Where doctors have often led to present on stage at medical conferences, trade shows and health and wellness expos, a new face in info-sharing presentation is sweeping the community of would-be patients in the most enjoyable and effective setting.

"Think about combining the classic Tupperware party with a post-college curriculum", starts education strategist Carmen R. DeWitt of Modern Pain Relief. "All you need is someone's large living room, an oversized TV (which is in practically every home in America by now) for the powerpoint, an engaging speaker about a topic like Stem Cell Therapy and a small spread of snacks and you've got yourself a cozy & dynamic medical seminar complete with a highly connective all-you-can-learn Q&A that outperforms any classroom setting! (See complete article in Journal of Modern Healing)

...........................................................

IF YOU ARE A CANCER-RELATED PROFESSIONAL AND WISH TO JOIN OUR GROUP, please drop us a line at: [email protected] and send us any information about you and your life's mission.

WHY JOIN NYCRA?: Through the spirit of networking, NYCRA allows for easier introductions, safer and healthier connecting through a more efficient use of the existing social & digital media. This media is also a highly-useful platform for for information sharing of educational or news material.

WE SUPPORT THE SUPPORTERS The world of cancer care is comprised of some of the most dedicated and compassionate individuals who committed much (if not most) of their lives into the pursuits of helping others. To truly get in the fight, there is no better way than to bond with colleagues and gain the support of our fellow do-gooders. AFAC and NYCRA has been established to bring support to the existing resources (that's YOU) in the form of increasing your web visibility, new exposure to your events or article posts and grow your alliance.

NETWORK BUILDING IN LINKEDIN: There's no denying that the internet brings the world closer! But unlike other websites, LINKEDIN is a special vibe over others because everyone here is a professional. That's the spirit of networking in action. You may find corporate owners, medical directors and others who have decision making power to help others (including fundraising orgs). This is just one of the ways that AFAC helps to bring visibility to our cancer related friends.

GROUP INTEGRITY & CONDUCT Once you have joined the group, the FORUM allows for easy POSTING of blog articles, links to interesting websites, videos or announcements... information that helps enrich others. Please start by reading the GROUP RULES . We respect the privacy and expectations of our many members and in order to get the best experience, we need to ensure that our group website is COMMERCIAL-FREE from solicitors and spammers. Because of this, we have a MODERATOR reviewing all posts & member applicants with the ability to flag any solicitous marketing posts that may otherwise be deemed "self-serving".

YOUR FIRST POST If you're a new member, WELCOME! We invite you to post a non-sales'y introduction of yourself to everyone in our home page and let people know who you are. We suggest to start your first post as a BRIEF intro of 100 words. Keep it about YOU and not as much about your work or service- that can happen later. As members of the cancer community, all members are compassionate to the cause and is a great place to build new connections based on your personal mission. Your intro should reflect this.

Powered by: AwarenessforaCure.org

Disclaimer & Copyright Notice: Copyright (c) 2021, IntermediaWorx inc. All Rights Reserved.  Additional rights shared by: The AngioFoundation (501c3) and the publishers of  Prevention101.org   & The NY Cancer Resource Alliance [ NYCRAlliance.org ].  Contents in this article are provided publicly for informational purposes within non-commercial use and not for purposes of resale, distribution, commercial display or performance. Unless otherwise indicated on this web based page, no reproduction of any or all materials of this page is allowed without express/written permission from the publishers.  Additional permission may be required from third-parties who have provided limited permission for our publishers to use their content, whereas licenses for some of this Content may contain additional terms. When such Content licenses contain additional terms, we will make these terms available to you on those pages (which his incorporated herein by reference).The publishers/producers of this site and its contents such as videos, graphics, text, and other materials published are not intended to be a substitute for professional medical advice, diagnosis, or treatment. For any questions you may have regarding a medical condition, please always seek the advice of your physician or a qualified health provider. Do not postpone or disregard any professional medical advice over something you may have seen or read on this website. If you think you may have a medical emergency, call your doctor or 9-1-1 immediately.  This website does not support, endorse or recommend any specific products, tests, physicians, procedures, treatment opinions or other information that may be mentioned on this site. Referencing any content or information seen or published in this website or shared by other visitors of this website is solely at your own risk. The publishers/producers of this Internet web site reserves the right, at its sole discretion, to modify, disable access to, or discontinue, temporarily or permanently, all or any part of this Internet web site or any information contained thereon without liability or notice to you.

• Scientific Advisory Committee
• Sponsors & Partners
• Ovarian Cancer Industry Council
• Events & Celebrity Supporters

Financial Stewardship

• Partners in Science Donors
• Digital Materials

Ovarian Cancer Research Alliance preserves the public trust by taking all reasonable steps to ensure rigorous accountability in its efforts, transparency in its financial operations, and stewardship of its donors’ funds. When you donate to OCRA, you can be sure your money is handled carefully and responsibly. Don’t just take our word for it: OCRA has earned the highest possible rating from Charity Navigator, meets the stringent Standards for Charity Accountability set forth by the Better Business Bureau’s Wise Giving Alliance, and we have a Gold rating from Guidestar.

Please explore this page to view our  financial statements  and  policies .

Financial Statements

Ovarian Cancer Research Alliance is a 501(c) 3 non profit organization. Our financial documents are public and available for viewing below.

Financial Statements from Ovarian Cancer Research Alliance:

• 2022: Form 990 | Financial Statement | 2022 Annual Report
• 2021: Form 990 | Financial Statement | 2021 Annual Report
• 2020: Form 990 | Financial Statement | 2020 Annual Report
• 2019: Form 990 | Financial Statement | 2019 Annual Report
• 2018: Form 990 | Financial Statement | 2018 Annual Report
• 2017: Form 990 | Financial Statement | 2017 Annual Report
• 2016:  Form 990 | Financial Statement

Financial Statements from the former Ovarian Cancer Research Fund:

• 2015:  Form 990 | Financial Statement
• 2014:  Form 990 | Financial Statement
• 2013:  Form 990 | Financial Statement

Financial Statements from the former Ovarian Cancer National Alliance:

• 2015: Form 990 | Financial Statement
• 2014: Form 990 | Financial Statement
• 
2013: Form 990 | Financial Statement

A 501(c)(3) organization, Ovarian Cancer Research Alliance receives funding from individual donors, foundations, corporations, state and federal government, and cause-marketing initiatives. Individual solicitations, direct mail, fundraising events, grant proposals, sponsorships, product sales, and special projects secure these funds.

Our mission is to remain objective in providing information to the ovarian cancer community; we do not endorse any particular treatment, therapy, clinical trial or product.

Ovarian Cancer Research Alliance is committed to:

• Ensuring that fundraising complies with all applicable federal and state regulations, including appropriate registrations, annual filings, and audits to comply with the Internal Revenue Code;
• Providing the public with access to its most recent financial reports and filings;
• Maintaining the confidentiality of donors’ information and ensuring any disclosures comply with all applicable laws;
• Accepting contributions from sources such as individuals, foundations, and for-profit institutions while ensuring that the positions of Ovarian Cancer Research Alliance on policy issues are never unduly or improperly influenced by contributors.